Background {#Sec1}
==========

The incidence of adenocarcinoma of the esophagogastric junction is increasing in Western and Eastern countries. However, the proposed strategies for the treatment in these patients are diverse, and there is no established consensus on the optimal treatment \[[@CR1]\]. We report a long-term survivor with recurrent esophagogastric junction adenocarcinoma who underwent constructive multimodal therapy, including surgical resection.

Case presentation {#Sec2}
=================

A 51-year-old man presented with an abnormal gastric shape on medical examination. Esophagogastroduodenoscopy revealed type 1 tumor of the esophagogastric junction (Fig. [1](#Fig1){ref-type="fig"}a, b). Pathological examination of the biopsied specimens showed a moderately tubular adenocarcinoma with mucinous adenocarcinoma. Abdominal computed tomography (CT) did not indicate swelling of any lymph node or distant metastasis. On the basis of these clinical and pathological findings, we diagnosed the patient with Siewert type II esophagogastric junction adenocarcinoma (T2 N0 M0 stage IB). Although we initially performed proximal gastrectomy in January 2009, we soon converted to total gastrectomy with D2 lymphadenectomy due to the intrasurgical detection of a lymph node metastasis in station no. 2. The resected specimen showed tumor measuring 25 × 17 mm (Fig. [2](#Fig2){ref-type="fig"}), and the tumor was identified as mucinous adenocarcinoma on the basis of histological classification (Fig. [3](#Fig3){ref-type="fig"}a, b). According to the pathological examination of resected specimens, his tumor was T1b N1 M0 stage IB and HER2 status was negative. He was followed up every 2 to 3 months without adjuvant chemotherapy by regular clinical diagnostic examinations, such as tumor marker studies (CEA and CA19-9) and computed tomography. Fig. 1Esophagogastroduodenoscopy revealed a type 1 tumor in the esophagogastric junction (**a**, **b**) Fig. 2Macroscopic findings of the resected stomach. The tumor size was 25 × 17 mm (arrow) Fig. 3Histopathological findings of the primary tumor. Original magnification × 40 (**a**). Original magnification × 400 (**b**)

In June 2009, CT showed an isolated small nodule measuring 3 mm in the right lower lobe of the lung. Because the lesion exhibited normal uptake on fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET), the patient was followed up with close observation only.

In June 2010, CT indicated that the lung nodule had increased to 8 mm in size (Fig. [4](#Fig4){ref-type="fig"}). We partially resected the right lower lung, including the nodule. Since pathological examination showed the resected lung tumor was a mucinous adenocarcinoma with positive expression of cytokeratin (CK) 7 and negative expression of CK 20, thyroid transcription factor-1, and apoprotein A, it was judged as a distant metastasis from the esophagogastric junction adenocarcinoma. HER2 status in lung metastatic lesion was not explored due to primary tumor with HER2 negative. Fig. 4Computed tomography showed an enlarged nodule in the right lower lung lobe (arrow)

After lung resection, he received adjuvant chemotherapy with S-1. The treatment schedule was the oral administration of S-1 (120 mg/body) for 4 weeks, followed by 2 weeks of rest, repeated every 6 weeks. This adjuvant chemotherapy with S-1 was continued for 1 year. Although a May 2013 CT showed swelling of the upper mediastinal lymph node, the maximum standardized uptake value (SUV~max~) in FDG-PET was 2.3. Consequently, he was followed up by observation. In September 2014, FDG-PET indicated that this node now demonstrated increased FDG uptake (SUV~max~, 2.8) (Fig. [5](#Fig5){ref-type="fig"}). The lymph node specimens obtained by ultrasonography-guided needle biopsy appeared to be mucinous adenocarcinoma, identical to this patient's esophagogastric junction cancer. He was enrolled in a clinical trial and received five courses of trastuzumab in combination with capecitabine and cisplatin. The therapeutic schedule included the oral administration of capecitabine (3000 mg/body) for 2 weeks, followed by 1 week of rest, repeated every 3 weeks, and administration of both cisplatin (80 mg/m^2^) and trastuzumab (8 mg/kg in the first course and 6 mg/kg after second courses) on day 1. Fig. 5Fluorine-18 fluorodeoxyglucose positron emission tomography indicated abnormal uptake (arrow) within the upper mediastinal lymph node

Following chemotherapy, CT showed decreased size of the metastatic lymph node. In April 2015, he underwent left upper mediastinal lymphadenectomy by the left cervical approach. Mucinous adenocarcinoma was identified by pathological examination. Although we proposed chemoradiotherapy after surgery, he refused our suggestion. Accordingly, he underwent radiation therapy with a total of 50.4 Gy introduced into the upper mediastinal field. In September 2015, he was treated with the oral administration of S-1 (80 mg/body) for 2 weeks, followed by 2 weeks of rest, repeated every 4 weeks. Since he could not continue chemotherapy because of grade 2 neutropenia and grade 1 fatigue, we stopped chemotherapy after only two courses. At 8 years and 4 months after the initial surgery, this patient exhibited no signs of disease recurrence on follow-up examinations.

Discussion {#Sec3}
==========

It is well known that the process of recurrence and the metastatic pathway are completely different from primary organs or histological types \[[@CR2]\]. Most patients with pulmonary metastases from gastric cancer have carcinomatous lymphangiomatosis or carcinomatous pleuritic \[[@CR3]\]. The incidence of surgically resectable solitary metastases is reportedly only 0.1% \[[@CR4]\], and the clinical significance of surgical resection remains unclear in patients with pulmonary metastases from gastric cancer. Table [1](#Tab1){ref-type="table"} summarizes six reports, published from 2000 to 2012, on Japanese patients who underwent surgical resection for pulmonary metastases from gastric cancer \[[@CR2], [@CR5]--[@CR9]\]. Table 1Reported case of resected lung metastasis from gastric cancer in JapanYearAuthorAgeSexDepth of invasionPathological stage*N*Histological typeType of gastrectomyDisease-free intervalAdjuvant chemotherapyNumber of pulmonary metastasesMetastatic lesionOutcome after gastrectomy2002Inoue et al. \[[@CR5]\]68MsmStage IaN0tub1DG8 yearsUnknown1LungA (15 years)2002Tamura et al. \[[@CR6]\]67MssStage IIAN1tub2TG5 years, 8 monthsUnknown1LungBrainD (6 years, 2 months)2002Tamura et al. \[[@CR6]\]47MseStage IIIAN1tub2TG4 years, 1 monthUnknown1LungChest wallD (5 years, 7 months)2002Tamura et al. \[[@CR6]\]73MseStage IIIAN1mucTG2 yearsUnknown1LungLiverD (2 years, 7 months)2002Tamura et al. \[[@CR6]\]65MmpStage IBN0tub2TG7 monthsUnknown1LungBrainD (1 year, 7 months)2007Sakaguchi et al. \[[@CR7]\]67FsiStage IIIA--papTG4 years, 1 month5FU + CDDP1LungA (10 years, 5 months)2007Sakaguchi et al. \[[@CR7]\]75MmpStage IB--papDG5 yearsUnknown1LungA (7 years, 9 months)2007Sakaguchi et al. \[[@CR7]\]57MssStage II--tub2DG4 yearsUnknown1LungA (5 years, 9 months)2007Sakaguchi et al. \[[@CR7]\]75MsmStage IB--tub2TG4 yearsUnknown1LungA (4 years, 8 months)2007Sakaguchi et al. \[[@CR7]\]57FssStage IB--tub2TG1 years, 8 monthsS-11LungA (3 years, 5 months)2007Sakaguchi et al. \[[@CR7]\]76FssStage II--tub1TG0 monthsUnknown1LungD (4 years, 11 months)2007Sakaguchi et al. \[[@CR7]\]84MssStage IB--tub1TG19 monthsUnknown1LungD (1 year, 10 months)2009Nishioka et al. \[[@CR8]\]40MseStage IIIAN1papPG4 yearsS-1 + CPT112LungA (7 years)2012Harada et al. \[[@CR2]\]55MseStage IIN0tub2TG3 yearsS-12LungAdrenal glandA (6 years, 9 months)2012Shimoyama et al. \[[@CR9]\]55MsiStage IVN3tub2DG7 years, 2 monthsUnknown1LungA (8 years, 5 months)2012Shimoyama et al. \[[@CR9]\]77MssStage IIN1tub1DG5 yearsUnknown1LungD (9 years, 8 months)2012Shimoyama et al. \[[@CR9]\]76MssStage IIN1tub2TG3 years, 7 monthsUnknown1LungLiverBrainD (4 years, 11 months)2012Shimoyama et al. \[[@CR9]\]80MssStage IB0tub2TG1 year, 6 monthsUnknown3LungD (3 years, 8 months)2019Our case51MsmStage IBN1mucTG1 years, 5 monthsS-1, cape+CDDP+Trastuzumab1LungA (8 years, 4 months)*sm* submucosa, *si* invasion of adjacent structures, *mp* muscularis propria, *se* serosa exposed, *ss* subserosa, *tub1* well-differentiated tubular adenocarcinoma, *pap* papillary adenocarcinoma, *tub2* moderately differentiated tubular adenocarcinoma, *muc* mucinous adenocarcinoma, *DG* distal gastrectomy, *TG* total gastrectomy, *PG* proximal gastrectomy, *5FU* fluorouracil, *CDDP* cisplatin, *cape* capecitabine, *CPT11* irinotecan, *A* alive, *D* dead

In the present case, tumor recurred within the lung and upper mediastinal lymph nodes metachronously. Interestingly, patients with synchronous metastasis of other organs in addition to pulmonary metastases tend to have poor prognosis (Table [1](#Tab1){ref-type="table"}). Since our patient had a metachronous recurrence of pulmonary and lymph node metastases after gastrectomy, his survival may be prolonged.

Presently, chemotherapy is the standard treatment in patients with unresectable advanced or recurrent gastric cancers. Overall survival was significantly better among patients with unresectable advanced or recurrent gastric cancer who were randomized to receive chemotherapy, compared with those who received supportive care only \[[@CR10]\]. The Gastric Cancer Treatment Guidelines, published by the Japanese Gastric Cancer Association in 2018, include recommended chemotherapies \[[@CR11]\]. Our patient received a trastuzumab-containing regimen, and his metastatic lymph node shrank after five courses. Recent advances in anticancer agents, including novel molecular-targeted drugs such as trastuzumab, have helped improve prognosis in these patients. Moreover, immune-checkpoint inhibitors such as nivolumab have clinical utility as third-line regimens in patients with unresectable advanced or recurrent gastric cancer \[[@CR12]\]. Multimodal treatments, including surgical resection, continue to improve prognosis in patients with advanced gastric cancer.

Conclusion {#Sec4}
==========

We report a long-term survivor of recurrent esophagogastric junction adenocarcinoma, managed with a multimodal treatment that included surgical resection and chemotherapy for metachronous metastases to the lung and upper mediastinal lymph nodes. In the near future, a large-cohort retrospective analysis will be required for assessing the clinical benefits of multimodal treatments.
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